Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 221

Sort by

Sort Order Select

Journal Articles

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark Hamilton, Ajlan Al Zaki, Lei Feng, Zachary Hunzeker, Dai Chihara, Hun Lee, Chitra Hosing, Laura Ebarle, Oluwadare Ajishegiri, Jason Westin, Sairah Ahmed, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2025-5485

Published: 2025

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2025-5994

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner, Francisco Vega, Deepa Sampath, Alessandra Ferrajoli, Kelly Chien, Elias Jabbour, Danielle Hammond, Nicholas Short, Koichi Takahashi, Nitin Jain, Jan Burger, Gautam Borthakur, William Wierda, Chitra Hosing, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2025-3653

Published: 2025

Journal Articles

Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome

Jillian Gunther, Auris Huen, Julia Dai, Swami Iyer, Carlos Torres-Cabala, Luis Fayad, Luis Malpica, Timothy Lin, Penny Fang, Susan Wu, Chelsea Pinnix, Jessie Xu, Ranjit Nair, Samer Srour, Rita Khouri, Jeremy Ramdial, Yago Nieto, Chitra Hosing, Bouthaina Dabaja

Blood (2025) 146 (Supplement 1): 3650.

https://doi.org/10.1182/blood-2025-3650

Published: 2025

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Blood (2025) 146 (Supplement 1): 378.

https://doi.org/10.1182/blood-2025-378

Published: 2025

Journal Articles

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Blood (2025) 146 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2025-1869

Published: 2025

Journal Articles

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Yosra Aljawai, Denai Milton, Rohtesh Mehta, David Marin, Yago Nieto, George Chen, Betul Oran, Portia Smallbone, Chitra Hosing, Oren Pasvolsky, Amin Alousi, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 168.

https://doi.org/10.1182/blood-2025-168

Published: 2025

Journal Articles

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Blood (2025) 146 (Supplement 1): 6058.

https://doi.org/10.1182/blood-2025-6058

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

Kunhwa Kim, Auris O Huen, Julia Dai, Rishabh Lohray, Bouthaina S. Dabaja, Jillian R. Gunther, Susan Y. Wu, Carlos P Torres-Cabala, Ranjit Nair, Luis Malpica, Yago Nieto, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 7448.

https://doi.org/10.1182/blood-2024-212007

Published: 2024

Journal Articles

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Yosra M. Aljawai, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Portia Smallbone, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2024) 144 (Supplement 1): 7441.

https://doi.org/10.1182/blood-2024-210279

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome

Optimizing essential, complex hematologic care for patients living with disabilities

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only